Higher C-reactive protein predicts worse prognosis in acute heart failure only in noninfected patients

Clinical Cardiology

Volumn 33, Issue 11, 2010, Pages 708-714

  Lourenço, Patrícia ^a   Paulo Araújo, José ^a   Paulo, Cristiana ^a   Mascarenhas, Joana ^a   Friões, Fernando ^a   Azevedo, Ana ^a   Bettencourt, Paulo ^a  

^a University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CAUSE OF DEATH; DIABETES MELLITUS; HOSPITAL READMISSION; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; COMMUNICABLE DISEASES; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; PORTUGAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 78649685751     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20812     Document Type: Article

References (24)

1. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147: 931-938.
2. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112: 1428-1434.
3. Xue C, Feng Y, Wo J, et al. Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure. N Z Med J 2006; 119: U2314.
4. Windram JD, Loh PH, Rigby AS, et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 2007; 153: 1048-1055.
5. Tanner H, Mohacsi P, Fuller-Bicer GA, et al. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant 2007; 26: 622-629.
6. Chirinos JA, Zambrano JP, Chakko S, et al. Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 2005; 95: 88-90.
7. Kaneko K, Kanda T, Yamauchi Y, et al. C-reactive protein in dilated cardiomyopathy. Cardiology 1999; 91: 215-219.
8. Lamparter S, Grimm W,. Predictive value of high-sensitivity C-reactive protein in patients with idiopathic dilated car- diomyopathy. Pacing Clin Electrophysiol 2005; 28: S233-S236.
9. Ronnow BS, Reyna SP, Muhlestein JB, et al. International Heart Collaborative Study Group. C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology 2005; 104: 196-201.
10. Ishikawa C, Tsutamoto T, Fujii M, et al. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006; 70: 857-863.
11. Mann DL,. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100: 999-1008.
12. Steele IC, Nugent AM, Maguire S, et al. Cytokine profile in chronic cardiac failure. Eur J Clin Invest 1996; 26: 1018-1022.
13. Paulus WJ,. How are cytokines activated in heart failure? Eur J Heart Fail 1999; 1: 309-312.
14. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002; 4: 331-336.
15. Siirilä-Waris K, Lassus J, Melin J, et al. FINN-AKVA Study Group. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006; 27: 3011-3017.
16. Villacorta H, Masetto AC, Mesquita ET,. C-reactive protein: an inflammatory marker with prognostic value in patients with decompensated heart failure [in English and Portuguese]. Arq Bras Cardiol 2007; 88: 585-589.
17. Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006; 151: 845-850.
18. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [published correction appears in Eur Heart J. 2010;12:416]. Eur Heart J 2008; 29: 2388-2442.
19. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
20. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-2174.
21. Ross JS, Chen J, Lin Z, et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail 2010; 3: 97-103.
22. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528-1536.
23. Ridker PM, Rifai N, Pfeffer MA, et al. Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-235.
24. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.